Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	1.61B
Revenue (ttm)	-665,000
Net Income (ttm)	-149.28M
Shares Out	109.82M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	875,614
Open	13.97
Previous Close	13.95
Day's Range	13.90 - 15.09
52-Week Range	2.60 - 16.96
Beta	-0.33
Analysts	Strong Buy
Price Target	17.43 (+18.65%)
Earnings Date	Nov 6, 2025

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Summary

According to 7 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $17.43, which is an increase of 18.65% from the latest price.

Price Target

$17.43

(18.65% upside)

Analyst Consensus: Strong Buy